Core Viewpoint - Palvella Therapeutics, Inc. has successfully closed an upsized public offering, raising $230 million to support the development of its therapies for rare skin diseases and vascular malformations [1][3]. Group 1: Offering Details - The public offering consisted of 1,840,000 shares of common stock, priced at $125.00 per share, including the full exercise of the underwriters' option for an additional 240,000 shares [1]. - The offering was managed by several financial institutions, including TD Cowen, Cantor, and Stifel, among others [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of Palvella's programs, specifically QTORIN rapamycin and QTORIN pitavastatin, as well as for general corporate purposes and research and development expenses [3]. Group 3: Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations without FDA-approved treatments [6]. - The company is developing a pipeline based on its patented QTORIN™ platform, with its lead product candidate being QTORIN™ 3.9% rapamycin anhydrous gel, aimed at treating various lymphatic and venous malformations [6][7].

Group 1 - Palvella Therapeutics, Inc. announced the pricing of its upsized public offering of 1,600,000 shares at $125.00 per share, with expected gross proceeds of $200 million [1] - The offering includes a 30-day option for underwriters to purchase an additional 240,000 shares [1] - The offering is expected to close on or about February 27, 2026, subject to customary closing conditions [1] Group 2 - The net proceeds from the offering will be used to support the development of programs including QTORIN rapamycin and QTORIN pitavastatin, as well as for working capital and general corporate purposes [3] - The offering is made pursuant to a shelf registration statement declared effective by the SEC on January 29, 2026 [4] Group 3 - Palvella is focused on developing therapies for serious, rare skin diseases and vascular malformations, with a pipeline based on its patented QTORIN™ platform [6] - The lead product candidate, QTORIN™ rapamycin, is being developed for microcystic lymphatic malformations and other conditions, while QTORIN™ pitavastatin is for the treatment of disseminated superficial actinic porokeratosis [6][7]